Cell Cycle Kinase Inhibitors Potentiate the Effect of 177lu-Lilotomab Satetraxetan in Treatment of Aggressive Diffuse Large B-Cell Lymphoma Cell Lines

癌症研究 弥漫性大B细胞淋巴瘤 放射免疫疗法 淋巴瘤 滤泡性淋巴瘤 细胞周期 细胞培养 医学 紫杉醇 化学 癌症 生物 免疫学 内科学 抗体 单克隆抗体 遗传学
作者
Gro Elise Rødland,Katrine B. Melhus,Jostein Dahle,Randi G. Syljuåsen,Sebastian Patzke
出处
期刊:Blood [Elsevier BV]
卷期号:132 (Supplement 1): 1371-1371
标识
DOI:10.1182/blood-2018-99-110200
摘要

Abstract Background CD37 is an internalizing transmembrane glycoprotein widely expressed on mature B-cells and B-cell malignancies. The next generation anti-CD37 radioimmunoconjugate (RIC) 177Lu-lilotomab satetraxetan (Betalutin®), containing the beta-emitting radionuclide lutetium-177, is currently being tested as one-time injection therapy in a clinical phase 2b trial for follicular lymphoma (FL) and phase 1 trial for diffuse large B-cell lymphoma (DLBCL). We recently reported the systems biology analysis of germinal center like (GCB) and activated B-cell like (ABC) DLBCL cell lines to CD37 targeting radioimmunotherapy (RIT) (Melhus, et al., PF642 at EHA23, Stockholm, 2018). 177Lu-Lilotomab satetraxetan showed generally promising activity against DLBCL cell lines, but treatment resistance was evident in a subset of cell lines. Resistance was not attributable to differences in CD37 expression nor correlated to genetic hallmarks of aggressiveness such as aberrations in TP53, BCL2 and MYC. In the present study we aimed at identifying resistance reversing drug combinations with 177Lu-lilotomab satetraxetan in two RIT resistant aggressive ABC-DLBCL cell lines. Materials and methods U-2932 and RIVA cells were treated for 18 hours with 177Lu-lilotomab satetraxetan (600 MBq/mg; 1 or 0.5 µg/ml), washed, and seeded on micro-well plates pre-printed with a drug library of 384 approved anti-cancer compounds at 10, 100, and 1000 nM (screen). For validation experiments, cells were treated with three different doses of 177Lu-lilotomab satetraxetan as described above and seeded on pre-printed plates with gradients of candidate hits ranging from 1-1280 nM. Cell viability was monitored at days 3 to 6 post seeding using a cell viability assay (RealTime-Glo™). Drug combinations were scored using Bliss and Chou-Talalay theorems. Results Compounds scoring in both cell lines included inhibitors targeting cell cycle kinases that regulate transition through mitosis, such as CDK1/2, AURKA/B, PLK1, as well as enzymes with important roles in DNA integrity surveillance and repair, such as topoisomerases. If the compounds also have or are being tested in clinical trials for treatment of non-Hodgkin lymphoma (NHL) they were considered candidates for further studies. PLK1 inhibitors BI2536 and GSK461364 potently inhibited cell proliferation at < 20 nM, with additional, but not synergistical benefit of combination with 177Lu-Lilotomab satetraxetan. The AURKA/B inhibitor Alisertib synergistically inhibited cell proliferation in combination treatment, but showed adverse effect at concentrations >160 nM, possibly owing to inhibition of a secondary target. The pan-CDK inhibitor JNJ-7706621 showed little effect alone but strongly synergized with 177Lu-lilotomab satetraxetan in inhibition of proliferation at doses > 80 nM. U-2932 and RIVA cells arrested in G2-phase with elevated DNA damage (flow cytometry; P-γ-H2AX and DNA staining) 18 hrs after treatment with 177Lu-lilotomab satetraxetan. Resistance reversal by anti-mitotics may thus underlie concomitant radiation during inhibitor mediated M-phase arrest of cells that eventually evaded G2-phase arrest. Conclusion In summary, combinatorial drug screening identified cell cycle kinase inhibitors as promising partners for combination treatment of aggressive DLBCL with 177Lu-lilotomab satetraxetan, warranting further exploration in pre-clinical models. Figure. Figure. Disclosures Rødland: Nordic Nanovector ASA: Patents & Royalties, Research Funding. Melhus:Nordic Nanovector ASA: Employment, Equity Ownership, Patents & Royalties. Dahle:Nordic Nanovector ASA: Employment, Equity Ownership, Patents & Royalties. Syljuåsen:Nordic Nanovector ASA: Patents & Royalties, Research Funding. Patzke:Nordic Nanovector ASA: Employment, Patents & Royalties.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
隐形曼青的应助被现代胡萝卜采纳,获得30
2秒前
榴莲发布了新的文献求助10
3秒前
学习发布了新的文献求助10
3秒前
穆有问题完成签到,获得积分10
4秒前
英姑的应助被初景采纳,获得150
4秒前
调皮芝麻完成签到,获得积分10
4秒前
4秒前
SciGPT的应助被哈基米德采纳,获得10
5秒前
赘婿的应助被羡鱼采纳,获得10
5秒前
Eliauk发布了新的文献求助50
5秒前
板凳饭团完成签到,获得积分10
6秒前
Nole的应助被11采纳,获得30
8秒前
DW的应助被Olive采纳,获得10
8秒前
9秒前
9秒前
满意妙梦完成签到,获得积分10
9秒前
无趣完成签到,获得积分20
10秒前
10秒前
一生所爱发布了新的文献求助10
11秒前
ff完成签到,获得积分10
11秒前
xiejingyu发布了新的文献求助10
12秒前
酷波er的应助被DREAMING采纳,获得10
12秒前
12秒前
刘刘宇航完成签到,获得积分20
14秒前
濯枝雨完成签到 ,获得积分10
14秒前
斯文败类的应助被LIUDAN采纳,获得10
15秒前
15秒前
RUSH发布了新的文献求助20
15秒前
灵巧的乌发布了新的文献求助10
15秒前
16秒前
16秒前
蔡正雄发布了新的文献求助10
16秒前
华雍完成签到,获得积分10
18秒前
魔幻的糜完成签到,获得积分10
19秒前
明亮白山发布了新的文献求助10
19秒前
小白发布了新的文献求助10
19秒前
科研通AI65的应助被刘刘宇航采纳,获得10
19秒前
852的应助被lzh采纳,获得10
19秒前
万能图书馆的应助被BPX采纳,获得10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183694
求助须知:如何正确求助?哪些是违规求助? 9572963
关于积分的说明 21828306
捐赠科研通 7780864
什么是DOI,文献DOI怎么找? 3434057
关于科研通互助平台的介绍 2558257
邀请新用户注册赠送积分活动 2480541